Summary

This article presents pooled data from three clinical trials of cangrelor, an intravenous adenosine diphosphate-receptor antagonist in patients undergoing percutaneous coronary intervention (PCI) demonstrating significant reductions in thrombotic complications without an increase in major bleeding. The efficacy of the novel, investigational agent cangrelor has been evaluated in three randomized, double-blind, clinical trials against clopidogrel or placebo in patients during and after PCI: CHAMPION PHOENIX [Bhatt DL et al. N Engl J Med 2013]; CHAMPION PLATFORM [Bhatt DL et al. N Engl J Med 2009]; and CHAMPION PCI [Harrington RA et al. N Engl J Med 2009].